Our lead heat shock protein 90 (Hsp90) inhibitor, IPI-504, is a small molecule drug candidate being developed jointly by Infinity and MedImmune, a division of AstraZeneca. The water-based formulation of IPI-504 is delivered as an intravenous infusion.

IPI-504 has been well-tolerated and has shown promising biological activity in clinical trials in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) and patients with advanced non-small cell lung cancer (NSCLC). IPI-504 is also being evaluated in a Phase 2 study in patients with hormone-refractory prostate cancer (HRPC) and in a Phase 1b study in combination with Taxotere® in patients with advanced solid tumors. Additional clinical trials for IPI-504 as both a single agent and in combination with marketed therapies are planned.

Data from clinical trials with IPI-504 are available in the publication archive.

IPI-504 has been shown in preclinical studies to inhibit Hsp90 potently and selectively, thereby killing cancer cells. In these preclinical studies, IPI-504 has demonstrated a broad potential to treat cancer as a single agent as well as in combination with existing anti-cancer drugs. In addition, IPI-504 preferentially targets and accumulates in tumor tissues. For these reasons, we believe that IPI-504 has broad potential for the treatment of patients with a wide variety of solid and hematological tumors, including cancers that are resistant to other drugs.

In October, Infinity was issued a patent (U.S. Patent No. 7,282,493) by the United States Patent and Trademark Office broadly covering IPI-504 and other related molecules useful for treating cancer. The patent includes composition of matter, pharmaceutical composition, method of treatment, and synthetic method claims.